AAQ1 Stock Overview
Develops, manufactures, and markets trauma products for orthopedics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
aap Implantate AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.98 |
| 52 Week High | €2.90 |
| 52 Week Low | €0.65 |
| Beta | -0.36 |
| 11 Month Change | -1.00% |
| 3 Month Change | 69.23% |
| 1 Year Change | 149.06% |
| 33 Year Change | -41.07% |
| 5 Year Change | -41.94% |
| Change since IPO | -98.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| AAQ1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.7% | 2.4% | 0.8% |
| 1Y | 149.1% | -5.0% | 9.1% |
Return vs Industry: AAQ1 exceeded the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: AAQ1 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| AAQ1 volatility | |
|---|---|
| AAQ1 Average Weekly Movement | 20.1% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AAQ1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AAQ1's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 111 | Rubino Di Girolamo | www.aap.de |
aap Implantate AG develops, manufactures, and markets trauma products for orthopedics. It offers LOQTEQ, an anatomical plating system for fracture treatment of ankle joint, knee, elbow, wrist, and shoulder; and straight plates and cannulated screws. The company sells its products directly to hospitals, purchasing groups, and hospital groups in Germany through a network of distributors.
aap Implantate AG Fundamentals Summary
| AAQ1 fundamental statistics | |
|---|---|
| Market cap | €22.40m |
| Earnings (TTM) | -€2.31m |
| Revenue (TTM) | €11.96m |
1.9x
P/S Ratio-9.7x
P/E RatioIs AAQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAQ1 income statement (TTM) | |
|---|---|
| Revenue | €11.96m |
| Cost of Revenue | €1.47m |
| Gross Profit | €10.49m |
| Other Expenses | €12.80m |
| Earnings | -€2.31m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 87.72% |
| Net Profit Margin | -19.32% |
| Debt/Equity Ratio | 8.1% |
How did AAQ1 perform over the long term?
See historical performance and comparison